Click on the company for more information on the subsidy award. Click on the parent name to reach the summary page for that parent company.
Company | Parent | Location | Subsidy Source | Year | Subsidy Value | Loan/Bailout Value | Type of Subsidy |
---|---|---|---|---|---|---|---|
Boehringer Ingelheim Vetmedica, Inc. | Eli Lilly | Iowa | state | 2010 | $5,275,484 | tax credit/rebate | |
Acorda Therapeutics | Acorda Therapeutics | New York | state | 2015 | $5,209,220 | tax credit/rebate | |
Pfizer, Inc. | Pfizer | Pennsylvania | state | 2011 | $5,195,497 | tax credit/rebate | |
Eli Lilly and Company | Eli Lilly | Pennsylvania | state | 2013 | $5,019,493 | tax credit/rebate | |
Pfizer Central Research | Pfizer | Connecticut | state | 2000 | $5,000,000 | grant | |
Regeneron Pharmaceuticals, Inc. (MH#2) | Regeneron Pharmaceuticals | New York | state | 2022 | $5,000,000 | tax credit/rebate | |
Merck Sharp & Dohme Corp. II | Merck | North Carolina | state | 2019 | $4,974,750 | grant | |
Regeneron Pharmacueticals, Inc. | Regeneron Pharmaceuticals | New York | state | 2003 | $4,885,774 | enterprise zone | |
Centocor Research & Development Inc. | Johnson & Johnson | Pennsylvania | state | 2008 | $4,806,417 | tax credit/rebate | |
Janssen Research & Development, LLC | Johnson & Johnson | Pennsylvania | state | 2017 | $4,768,953 | tax credit/rebate | |
Novo Nordisk Research Center Seattle, Inc. | Novo Holdings A/S | Washington | state | 2020 | $4,725,452 | tax credit/rebate | |
Novo Nordisk Research Center Seattle, Inc. | Novo Holdings A/S | Washington | state | 2021 | $4,725,452 | tax credit/rebate | |
Novozymes, Inc. | Novo Holdings A/S | United States | federal | 2008 | $4,694,082 | federal grant | |
Amneal Pharmaceuticals LLC and Kashiv Pharma, LLC | Amneal Pharmaceuticals | New Jersey | state | 2010 | $4,638,000 | grant | |
Astellas US LLC and its subsidiaries and related entities | Astellas Pharma | Illinois | state | 2016 | $4,515,115 | tax credit/rebate | |
Takeda Pharmaceuticals North America, Inc. | Takeda Pharmaceutical | Illinois | state | 2009 | $4,511,785 | tax credit/rebate | |
GlaxoSmithkline Holdings Americas , Inc. | GlaxoSmithKline | North Carolina | state | 2013 | $4,414,142 | tax credit/rebate | |
NPS Pharmaceuticals, Inc. | Takeda Pharmaceutical | New Jersey | state | 2003 | $4,371,200 | grant | |
Valeant Pharmaceuticals North America LLC and | Bausch Health | New Jersey | state | 2003 | $4,325,100 | grant | |
Regeneron Pharmaceuticals | Regeneron Pharmaceuticals | New York | local | 2021 | $4,324,671 | tax credit/rebate | |
Merck Sharp & Dohme Corp. | Merck | North Carolina | state | 2016 | $4,302,041 | tax credit/rebate | |
GlaxoSmithKline, LLC ( f/k/a SmithKline Beecham Corporation) | GlaxoSmithKline | Pennsylvania | state | 2012 | $4,247,696 | tax credit/rebate | |
Mylan Technologies, Inc | Viatris | Vermont | state | 2012 | $4,228,373 | grant | |
Bristol-Myers Squibb Company | Bristol-Myers Squibb | New Jersey | state | 1997 | $4,200,000 | grant | |
PAREXEL International, LLC | Parexel International | North Carolina | state | 2019 | $4,194,000 | grant | |
Amneal Pharmaceutical of NY, LLC | Amneal Pharmaceuticals | New York | state | 2015 | $4,151,414 | enterprise zone | |
Amneal Pharmaceutical of NY, LLC | Amneal Pharmaceuticals | New York | state | 2015 | $4,151,414 | enterprise zone | |
GlaxoSmithkline Holdings Americas , Inc. | GlaxoSmithKline | North Carolina | state | 2016 | $4,121,650 | tax credit/rebate | |
Wyeth Holdings Corporation | Pfizer | North Carolina | state | 2013 | $4,097,786 | tax credit/rebate | |
Pfizer, Inc. | Pfizer | Pennsylvania | state | 2010 | $4,091,278 | tax credit/rebate | |
GlaxoSmithkline Holdings Americas , Inc. | GlaxoSmithKline | North Carolina | state | 2011 | $4,039,279 | tax credit/rebate | |
GlaxoSmithKline Holdings Americas , Inc. | GlaxoSmithKline | North Carolina | state | 2012 | $4,025,543 | tax credit/rebate | |
GlaxoSmithKline | GlaxoSmithKline | United States | federal | 2012 | $4,011,709 | federal grant | |
Cephalon, Inc. | Teva Pharmaceutical Industries | Pennsylvania | state | $4,000,000 | grant | ||
SAFC Carlsbad, Inc. | Merck KGaA (EMD) | California | state | 2019 | $4,000,000 | tax credit/rebate | |
Intervet Inc. | Merck | New Jersey | state | 2012 | $3,981,600 | grant | |
JOM Pharmaceutical Services, Inc. | Johnson & Johnson | Kentucky | state | 2007 | $3,960,000 | tax credit/rebate | |
Merck & Co. Inc. | Merck | New Jersey | state | 2000 | $3,948,650 | grant | |
Teva Pharmaceuticals | Teva Pharmaceutical Industries | Kansas | state | 2014 | $3,861,454 | grant | |
Genentech USA Inc. | Roche | Oregon | state | 2012 | $3,817,197 | property tax abatement | |
Pfizer, Inc. | Pfizer | New York | local | 2006 | $3,750,210 | tax credit/rebate; property tax abatement | |
RegeneronN | Regeneron Pharmaceuticals | New York | local | 2021 | $3,713,660 | tax credit/rebate | |
Astellas US LLC and its subsidiaries and related entities | Astellas Pharma | Illinois | state | 2015 | $3,701,242 | tax credit/rebate | |
IMMUNEX CORPORATION | Amgen | Washington | state | 2008 | $3,658,748 | tax credit/rebate | |
IMMUNEX CORPORATION | Amgen | Washington | state | 2007 | $3,626,627 | tax credit/rebate | |
IMMUNEX CORPORATION | Amgen | Washington | state | 2009 | $3,626,627 | tax credit/rebate | |
Novartis Vaccines and Diagnostics | Novartis | North Carolina | state | 2010 | $3,609,000 | grant | |
IMMUNEX CORPORATION | Amgen | Washington | state | 2011 | $3,568,422 | tax credit/rebate | |
IMMUNEX CORPORATION | Amgen | Washington | state | 2010 | $3,568,422 | tax credit/rebate | |
Eli Lilly and Company | Eli Lilly | Pennsylvania | state | 2012 | $3,552,766 | tax credit/rebate | |
Amyris, Inc. | Amyris | United States | federal | 2016 | $3,549,805 | federal grant | |
Fort Dodge Animal Health | Zoetis | Iowa | state | 2004 | $3,500,000 | grant | |
Shire HGT, Inc. | Takeda Pharmaceutical | Massachusetts | state | 2011 | $3,500,000 | tax credit/rebate | |
Bausch & Lomb Incorporated | Bausch Health | New Jersey | state | 2008 | $3,500,000 | grant | |
Bristol-Myers Squibb Co. | Bristol-Myers Squibb | Florida | state | 2014 | $3,500,000 | grant | |
Wyeth Holdings Corporation | Pfizer | North Carolina | state | 2014 | $3,476,438 | tax credit/rebate | |
Janssen Research & Development, LLC ( f/k/a J&J Pharmaceutical Research & Development LLC) | Johnson & Johnson | Pennsylvania | state | 2013 | $3,468,471 | tax credit/rebate | |
Immunex RI Corporation | Amgen | Rhode Island | state | 2018 | $3,450,000 | tax credit/rebate | |
Astellas US LLC and its subsidiaries and related entities | Astellas Pharma | Illinois | state | 2014 | $3,398,678 | tax credit/rebate | |
GLAXOSMITHKLINE LLC | GlaxoSmithKline | Pennsylvania | state | 2020 | $3,388,900 | tax credit/rebate | |
GlaxoSmithKline, LLC (f/k/a SmithKline Beecham Corporation) | GlaxoSmithKline | Pennsylvania | state | 2014 | $3,353,317 | tax credit/rebate | |
Genentech Inc | Roche | Oregon | state | 2013 | $3,340,842 | tax credit/rebate | |
Regeneron Warehouse Expansion | Regeneron Pharmaceuticals | New York | local | 2020 | $3,300,130 | tax credit/rebate | |
Pfizer, Inc. | Pfizer | New York | local | 2005 | $3,276,473 | tax credit/rebate; property tax abatement | |
Immunex RI Corporation | Amgen | Rhode Island | state | 2018 | $3,255,000 | tax credit/rebate | |
Boehringer Ingelheim Vetmedica, Inc. | Eli Lilly | Iowa | state | 2012 | $3,239,000 | grant | |
PHARMACIA CORPORATION | Pfizer | Missouri | state | 2002 | $3,235,374 | tax credit/rebate | |
Alere, Inc | Abbott Laboratories | Missouri | state | 2017 | $3,220,080 | tax credit/rebate | |
Regeneron Pharmaceuticals, Inc. | Regeneron Pharmaceuticals | New York | local | 2016 | $3,166,516 | tax credit/rebate | |
Regeneron Pharmaceuticals | Regeneron Pharmaceuticals | New York | local | 2020 | $3,137,267 | tax credit/rebate | |
Doral Arrowwood (Pfizer) | Pfizer | New York | local | 2004 | $3,137,110 | tax credit/rebate; property tax abatement | |
Genentech Inc | Roche | Oregon | local | 2023 | $3,134,511 | property tax abatement | |
Emergent Biosolutions | Emergent BioSolutions | Michigan | state | 2009 | $3,090,000 | tax credit/rebate | |
Watson Pharmaceuticals, Inc. and Affiliates | Teva Pharmaceutical Industries | New Jersey | state | 2009 | $3,038,000 | grant | |
Novo Nordisk Pharmaceutical | Novo Holdings A/S | North Carolina | state | 2010 | $3,032,000 | grant | |
Purdue Pharma, LP | Purdue Pharma | Connecticut | state | 2001 | $3,000,000 | grant/loan hybrid program | |
Hospira, Inc. and Subsidiaries | Pfizer | Illinois | state | 2005 | $3,000,000 | grant | |
Centocor, Inc. | Johnson & Johnson | Pennsylvania | state | $3,000,000 | tax credit/rebate | ||
Shire Human Genetic Therapies, Inc | Takeda Pharmaceutical | Massachusetts | state | 2012 | $3,000,000 | tax credit/rebate | |
Exelixis, Inc. | Exelixis | California | state | 2019 | $3,000,000 | tax credit/rebate | |
Bausch & Lomb Incorporated(2) | Bausch Health | New York | state | 2019 | $3,000,000 | tax credit/rebate | |
Bristol Myers Squibb Company | Bristol-Myers Squibb | Arizona | state | 2022 | $3,000,000 | tax credit/rebate | |
SmithKline Beecham Corporation DBA GlaxoSmithKline | GlaxoSmithKline | Pennsylvania | state | 2008 | $2,990,917 | tax credit/rebate | |
Regeneron Pharmaceuticals, Inc. | Regeneron Pharmaceuticals | New York | local | 2017 | $2,960,521 | tax credit/rebate | |
Pfizer, Inc. | Pfizer | New York | state | 2003 | $2,956,000 | enterprise zone | |
Merck & Co., Inc. | Merck | North Carolina | state | 2008 | $2,940,954 | tax credit/rebate | |
Hospira, Inc. and Subsidiaries | Pfizer | Illinois | state | 2008 | $2,872,836 | tax credit/rebate | |
SYNTHES (U.S.A.) | Johnson & Johnson | New York | state | 2007 | $2,870,000 | enterprise zone | |
Wyeth Holdings Corporation | Pfizer | North Carolina | state | 2009 | $2,868,194 | tax credit/rebate | |
OSI Pharmaceuticals/(OSI) Ardsley | Astellas Pharma | New York | local | 2010 | $2,865,573 | tax credit/rebate; property tax abatement | |
Regeneron Pharmaceuticals | Regeneron Pharmaceuticals | New York | local | 2008 | $2,849,428 | tax credit/rebate; property tax abatement | |
Emergent Biosolutions | Emergent BioSolutions | Michigan | state | 2012 | $2,821,980 | tax increment financing | |
Sanofi-Aventis U.S. LLC and Sanofi-Aventis U.S. In | Sanofi | New Jersey | state | 1997 | $2,784,000 | grant | |
Pfizer, Inc. | Pfizer | New York | state | 2002 | $2,783,900 | enterprise zone | |
Bristol-Myers Squibb Co. | Bristol-Myers Squibb | Florida | state | 2014 | $2,779,200 | tax credit/rebate | |
Merck & Co., Inc. | Merck | North Carolina | state | 2011 | $2,774,342 | tax credit/rebate | |
PBM Nutritionals, LLC | Perrigo | Vermont | state | 2004 | $2,755,595 | tax credit/rebate; property tax abatement | |
ImClone Systems Corporation | Eli Lilly | New Jersey | state | 2001 | $2,755,200 | grant | |
Pfizer, Inc. | Pfizer | Pennsylvania | state | 2009 | $2,715,300 | tax credit/rebate | |
AstraZeneca Pharmaceuticals LP | AstraZeneca | United States | federal | 2012 | $2,713,491 | federal grant | |
SYNTHES (U.S.A.) | Johnson & Johnson | New York | state | 2006 | $2,697,365 | enterprise zone |